| Literature DB >> 35070500 |
Peng Wang1, Zexin Zhang1, Bin Yin1, Jiayuan Li2, Cheng Xialin1, Wenqin Lian1, Yingjun Su3, Chiyu Jia1.
Abstract
BACKGROUND: Burn patients are prone to infection as well as immunosuppression, which is a significant cause of death. Currently, there is a lack of prognostic biomarkers for immunosuppression in burn patients. This study was conducted to identify immune-related genes that are prognosis biomarkers in post-burn immunosuppression and potential targets for immunotherapy.Entities:
Keywords: Immune-related cell; Post-burn immunosuppression; Prognostic biomarkers; Targets of immunotherapy; miRNA
Year: 2022 PMID: 35070500 PMCID: PMC8761370 DOI: 10.7717/peerj.12680
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1A graphical summary of the research design.
Clinical data from burn patients in GSE37069 and GSE19743 (datasets utilized to screen differentially expressed genes).
| Group (burn) | Sex | Age | Time of sampling | ||
|---|---|---|---|---|---|
|
| Male | Female | |||
|
| 28 | 24 | 4 | 37.61 ± 7.98 | 439.28 ± 117.86 |
|
| 81 | 57 | 24 | 37.41 ± 10.45 | 411.92 ± 124.76 |
|
| 0.109 | 0.271 | 0.311 | ||
Clinical data from burn patients in GSE37069 and GSE19743 (datasets utilized to screen differentially expressed genes).
| Group | Sex | Age | TBSA | Time of sampling | |||
|---|---|---|---|---|---|---|---|
|
| Male | Female | Severe (30–49) | Major (49–100) | |||
| Death | 23 | 19 | 4 | 40.73 ± 7.67 | 3 | 20 | 422.24 ± 122.32 |
| Survival | 81 | 70 | 11 | 40.67 ± 10.74 | 21 | 60 | 393.33 ± 113.19 |
|
| 0.147 | 0.974 | 0.001 | 0.544 | |||
Univariate logistic regression analysis.
| Factors |
|
| OR | 95% CI |
|---|---|---|---|---|
| NFATC2 | −5.161 | 1.235E−07 | 0.006 | [0.001–0.039] |
| RORA | −0.851 | 7.000E−06 | 0.427 | [0.295–0.618] |
| CAMK4 | −5.268 | 6.053E−09 | 0.004 | [0.001–0.024] |
| CAMK2D | −1.278 | 9.600E−05 | 0.276 | [0.145–0.527] |
| TBSA (50%) | 1.483 | 0.008 | 4.407 | [1.466–13.254] |
| Sex (1 = Female) | 0.434 | 0.278 | 0.648 | [0.296–1.419] |
| Age | 0.011 | 0.270 | 1.011 | [0.991–1.032] |
Multivariate logistic regression analysis.
| Factors |
|
| OR | 95% CI |
|---|---|---|---|---|
| NFATC2 | −4.714 | 4.100E−05 | 0.006 | [0.001–0.085] |
| RORA | −0.896 | 4.000E−03 | 0.427 | [0.223–0.748] |
| CAMK4 | −2.799 | 8.000E−03 | 0.004 | [0.008–0.488] |
| CAMK2D | 0.077 | 0.781 | – | – |
| TBSA (>50%) | 1.332 | 0.248 | – | – |
List of primers used in reverse transcription-quantitative PCR.
| Gene name | Real-time quantitative PCR primer (5′to 3′) |
|---|---|
|
| F: 5′-CGATTCGGAGAGCCGGATAG-3′ |
| R: 5′-TGGGACGGAGTGATCTCGAT-3′ | |
|
| F: 5′-AAAAACATGGAGTCAGCTCCG-3′ |
| R: 5′-AGTGTTGGCAGCGGTTTCTA-3′ | |
|
| F: 5′-ACA GAT GCA AAC AGA AGG GGA-3′ |
| R: 5′-TTG GAT GTG AGA GGC GAA GAA-3′ | |
|
| F: 5′-CTC TTG TTT TGC TGT TGG GCT-3′ |
| R: 5′-TGC TGA GAC ATT TGA GTC CGA-3′ | |
|
| F: 5′-CCAGGTGGTCTCCTCTGA-3′ |
| R: 5′-GCTGTAGCCAAATCGTTGT-3′ | |
| miR-212-3p | F: 5′-CGCGAGATCAGAAGGTGATT-3′ |
| R: 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGCCAC-3′ |
Figure 2Results of different analyses in GSE19743 and GSE37069.
Up-regulated DEGs are red while down-regulated DEGs are blue (|logFC| ≥ 1.5, p < 0.05). (A) GSE19743 had a total of 2,315 DEGs (605 up- and 1,710 down-regulated). (B) GSE37069 had a total of 961 DEGs (438 up- and 523 down-regulated). (C) Two hundred ninety-nine common up DEGs. (D) Four hundred forty-six common down DEGs.
Figure 3Results of immune infiltration analysis.
Compared with the control group, burn patients had significantly decreased Th-cells (CD4+) (naive, memory resting, and memory-activated), T cells gamma delta, M2, B cells naïve, and NK cells resting, significantly higher M0 macrophages, plasma cells and neutrophils, and no difference in resting mast cells, M1, monocytes and eosinophils.
Figure 4GO, GSEA, and KEGG results.
The abscissa is the ratio of the number of genes in the pathway to the total genes. The redder the color, the smaller the FDR, and the larger the circle, the more enriched the genes. (A, B) Biological process in GO enrichment analysis showed that common up genes were mainly enriched in the innate immune responses such as neutrophil activation, while common down genes were mainly enriched in adapted immune responses such as the T-cell receptor signaling pathway. (C) The T cell receptor signaling pathway was also a result from the KEGG enrichment analysis in common down genes. (D) T-cell receptor signaling pathway. (E) Graft versus host disease. (F) Autoimmune thyroid disease. (G) Allograft rejection. (H, I) The network diagram of the interactions between the DEGs in the biological process enrichment analysis using the ClueGo plug-in of Cytoscape. (H) Each circle represents a pathway, and circles with similar functions form a module. The multiple colors in the same circle represent that this pathway participated in multiple modules. Module names are either red (meaning that the modules were mainly enriched with common up genes), blue (the modules were mainly enriched with common down genes), or black (the genes enriched in the modules did not have significant differences between the two groups). Genes in pathways related to the activation of T cells, especially Th-cells, were downregulated, while genes in pathways related to the innate immune response, such as neutrophil activation, were up-regulated. (I) The pie chart represents the proportion of genes in each pathway from the total number of Cluster 1 (common up genes) and (J) Cluster 2 (common down genes) genes.
Immune-related genes in GO, KEGG, and GESA enrichment analysis.
| ID | Term | FDR | Genes |
|---|---|---|---|
|
| innate immune response | 1.72E−06 |
|
|
| phagocytosis, engulfment | 1.09E−05 |
|
|
| positive regulation of B cell activation | 2.69E−05 |
|
|
| defense response to bacterium | 3.54E−05 |
|
|
| phagocytosis, recognition | 4.29E−05 |
|
|
| immune response | 4.30E−05 |
|
|
| B cell receptor signaling pathway | 4.38E−05 |
|
|
| antibacterial humoral response | 5.51E−05 |
|
|
| T cell costimulation | 7.04E−05 |
|
|
| positive regulation of T cell activation | 3.20E−04 |
|
|
| T cell receptor signaling pathway | 4.33E−04 |
|
|
| leukocyte migration | 5.50E−04 |
|
| hsa05320 | Autoimmune thyroid disease | 8.48E−04 | |
|
| regulation of transcription, DNA-templated | 8.75E−04 | |
|
| adaptive immune response | 9.56E−04 | |
| hsa04660 | T cell receptor signaling pathway | 1.31E−03 |
|
|
| regulation of immune response | 1.43E−03 | |
| hsa05166 | HTLV-I infection | 1.44E−03 |
|
| hsa04612 | Antigen processing and presentation | 1.56E−03 | |
|
| cytokine production | 1.75E−03 | |
|
| complement activation, classical pathway | 1.81E−03 |
|
| hsa05332 | Graft- | 2.36E−03 |
|
| hsa04672 | Intestinal immune network for IgA production | 3.72E−03 | |
| hsa05330 | Allograft rejection | 4.97E−03 |
|
| hsa05321 | Inflammatory bowel disease (IBD) | 8.00E−03 |
|
| hsa04940 | Type I diabetes mellitus | 0.001100442 |
|
| hsa05152 | Tuberculosis | 0.001517592 |
|
| hsa05416 | Viral myocarditis | 0.00157646 |
|
| hsa05323 | Rheumatoid arthritis | 0.002170232 | |
| hsa04650 | Natural killer cell mediated cytotoxicity | 0.003601034 |
DEMs between thermal-stimulated epidermal stem cells and controls.
| miRNA ID | log2 (fold change) | Adj. |
|---|---|---|
| Up-regulated miRNA | ||
| hsa-miR-4485-3p | 4.2279 | 1.2 × 10−7 |
| hsa-miR-1973 | 6.9388 | 2.1 × 10−4 |
| hsa-miR-548j-5p | 6.6339 | 7.2 × 10−4 |
| hsa-miR-212-3p | 6.6339 | 7.2 × 10−4 |
| hsa-miR-4461 | 6.6339 | 7.2 × 10−4 |
| hsa-miR-4510 | 6.5464 | 1.0 × 10−3 |
| hsa-miR-3128 | 6.5464 | 1.0 × 10−3 |
| hsa-miR-549a | 6.4534 | 1.4 × 10−3 |
| hsa-miR-494-3p | 6.3539 | 1.9 × 10−3 |
| hsa-miR-7641 | 6.3539 | 1.9 × 10−3 |
| hsa-miR-1976 | 6.3539 | 1.9 × 10−3 |
| hsa-miR-6868-3p | 6.3539 | 1.9 × 10−3 |
| hsa-miR-548u | 6.3539 | 1.9 × 10−3 |
| hsa-miR-2116-3p | 6.2470 | 2.8 × 10−3 |
| hsa-miR-3614-5p | 6.2470 | 2.8 × 10−3 |
| hsa-miR-744-3p | 6.2470 | 2.8 × 10−3 |
| hsa-miR-1287-5p | 6.2470 | 2.8 × 10−3 |
| hsa-miR-3064-5p | 6.2470 | 2.8 × 10−3 |
| hsa-miR-181b-2-3p | 6.2470 | 2.8 × 10−3 |
| hsa-miR-3176 | 6.1313 | 4.1 × 10−3 |
| hsa-miR-516b-5p | 6.0058 | 6.1 × 10−3 |
| hsa-miR-338-5p | 6.0058 | 6.1 × 10−3 |
| hsa-miR-4746-5p | 6.0058 | 6.1 × 10−3 |
| hsa-miR-20a-3p | 6.0058 | 6.1 × 10−3 |
| hsa-miR-3688-3p | 6.0058 | 6.1 × 10−3 |
| hsa-miR-3179 | 6.0058 | 6.1 × 10−3 |
| hsa-miR-6514-3p | 5.8684 | 9.2 × 10−3 |
| hsa-miR-1237-3p | 5.8684 | 9.2 × 10−3 |
| hsa-miR-431-5p | 5.8684 | 9.2 × 10−3 |
| hsa-miR-382-3p | 5.8684 | 9.2 × 10−3 |
| hsa-miR-134-5p | 5.8684 | 9.2 × 10−3 |
| hsa-miR-4659a-3p | 5.8684 | 9.2 × 10−3 |
| hsa-miR-409-5p | 5.8684 | 9.2 × 10−3 |
| Down-regulated miRNA | ||
| hsa-miR-4520-5p | −6.8054 | 2.9 × 10−4 |
| hsa-miR-4661-5p | −6.4835 | 1.0 × 10−3 |
| hsa-miR-191-3p | −6.3904 | 1.4 × 10−3 |
| hsa-miR-129-5p | −6.3904 | 1.4 × 10−3 |
| hsa-miR-147b | −6.2908 | 1.9 × 10−3 |
| hsa-miR-6868-3p | −6.2908 | 1.9 × 10−3 |
| hsa-miR-323a-3p | −6.1839 | 2.8 × 10−3 |
| hsa-miR-6515-5p | −6.1839 | 2.8 × 10−3 |
| hsa-miR-1295a | −6.1839 | 2.8 × 10−3 |
| hsa-miR-1248 | −6.1839 | 2.8 × 10−3 |
| hsa-miR-193a-3p | −6.0685 | 4.1 × 10−3 |
| hsa-miR-1294 | −6.0685 | 4.1 × 10−3 |
| hsa-miR-149-3p | −6.0685 | 4.1 × 10−3 |
| hsa-miR-6887-3p | −5.9430 | 6.1 × 10−3 |
| hsa-miR-510-5p | −5.9430 | 6.1 × 10−3 |
| hsa-miR-486-5p | −1.7053 | 7.4 × 10−3 |
| hsa-miR-2277-5p | −5.8053 | 9.2 × 10−3 |
| hsa-miR-6806-3p | −5.8053 | 9.2 × 10−3 |
| hsa-miR-4683 | −5.8053 | 9.2 × 10−3 |
| hsa-miR-4504 | −5.8053 | 9.2 × 10−3 |
| hsa-miR-29b-2-5p | −5.8053 | 9.2 × 10−3 |
Figure 5Network of miRNA and mRNA.
(A) A total of 11 miRNAs were predicted using three databases at the same time, which are represented by circles in the network. The 11 differently expressed miRNAs had a total of 321 targeted mRNAs, which are represented by squares in the network. The red modules in the network were also immune-related genes, and the blue modules were not included in the immune-related genes. (B) There are 168 immune-related genes and 321 miRNA target genes. (C) There are four intersections among them.
Figure 6Relationship between key gene and CIC expression.
(A) Common expression relationship between key genes and CICs. (B) Correlation between NFATC2 and CD4-naive T cells. (C) Correlation between RORA and CD4-naive T cells. (D) Correlation between CAMK4 and CD4-naive T cells. (E) Correlation between CAMK2D and CD4-naive T cells.
Figure 7Differences in the expression profiles of key genes between surviving and non-surviving patients.
Figure 8Different expression profiles between burn patients and health controls in GSE77791.
(A) Heat map of GSE77791 (Top 100). (B–E) Key genes were significantly different between survival and non-survival patients.
Figure 9Results of the regression model.
(A, B) ROC curve of key genes in burn patients in GSE19743 and GSE77791. (C) The nomogram of the multivariate logistic regression, (D) calibration, and (E) ROC curves in GSE77791. (F) Validation results of logistic regression model in GSE19743 (p < 0.05).
Figure 10The results of qRT-PCR regarding NFATC2, RORA, CAMK4, CAMK2D, mir-212-3p, miR-3064-5p, miR-494-3p, and miR-129-5p. “*” means (p < 0.05), “**” means (p < 0.01), “***” means (p < 0.001), and “ns” means no difference.